Open AccessLncRNA OR2A1‐AS1 index predicts survival in germinal center‐like diffuse large B‐cell lymphoma
Author(s) -
Ye Shuting,
Ying Weiwei,
Lin Yi,
Hou Zhengjun,
Su Meiyun
Publication year - 2022
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.24680
Subject(s) - diffuse large b cell lymphoma , international prognostic index , germinal center , lymphoma , long non coding rna , cancer research , biology , oncology , medicine , gene , b cell , rna , immunology , genetics , antibody
Background Diffuse large B‐cell lymphoma (DLBCL) is a highly aggressive form of non‐Hodgkin lymphoma. Long noncoding RNA (lncRNA) has been evaluated as prognostic markers in various carcinomas. However, the prognostic value of the lncRNA index in DLBCL has not been fully understood. Hence, this study aimed to identify the prognostic value of lncRNA olfactory receptor family 2 subfamily A member 1‐antisense RNA 1 (OR2A1‐AS1) in DLBCL. Methods The Gene Expression Omnibus (GEO) database was used to obtain the GSE97336 dataset comprising lncRNA expression profiles. Quantitative reverse transcription polymerase chain reaction (QRT‐PCR) was conducted to evaluate the expression of OR2A1‐AS1 in 98 cases of DLBCL. Results OR2A1‐AS1 expression was considerably reduced in DLBCL patients, reduced OR2A1‐AS1 expression was linked to a shorter overall survival (OS) and progression‐free survival (PFS) in DLBCL patients, especially those with the germinal center B‐cell‐like subtype (GCB). Multivariate analysis (MVA) revealed that the OR2A1‐AS1 index had prognostic significance. Patients with low OR2A1‐AS1 expression have a poor prognosis. Conclusions OR2A1‐AS may represent an effective predictor of patients' outcomes with DLBCL.